Scientific Program

Preliminary (last update 09/04/19)

*** subject to changes ***

General outline of the program

We will kick off with a precongress Resident Workshop on Wednesday 22 May.

For the main congress, again we will have 3 half-day Themed Sessions, where the next subjects will be discussed in-depth by experts in that field:

On Saturday 25 May ESVONC will organize the very first symposium for veterinary nurses and technicians: for the program, see on this link.

There will be 2 social events:


-----------------------------------------------------

Programs in detail

This program is RACE approved: click to verify

Program Number: 36457, Provider Number: 1385, CE Hours:Vet: 11.50, Vet Tech: 4.25, Subject Matter Categories:Medical Program, Delivery Methods:Seminar/Lecture



Resident's workshop - Wednesday 22 May 2019

timetitlespeaker
Radiation therapy and photodynamic therapy
15:30-16:15Radiation biology – fundamental concepts for medical oncologists 
dr. Carla Rohrer
16:15-17:00Techniques in radiation therapy: 3DCRT, IMRT and beyond 
dr. Carla Rohrer
17:00-17:30Coffee break
17:30-18:15Brachytherapy and plesiotherapy in veterinary oncology
dr. Jérôme Benoit
18:15-19:00Photodynamic therapy in veterinary oncology: principles and applications
dr. Julia Buchholz


Main Program - Thursday 23 May 2019 

timetitlespeaker
08h00-09h00Registration opens

Themed session: Histiocytic proliferative diseases

09:00-09:45Key note lecture: Current understanding of histiocytic proliferative diseases
dr. Jérôme Abadie, Nantes
09:45-10:30Pathophysiological and genetic mechanisms associated with histiocytic malignancies
dr. Benoit Hédan, Nantes
10:30-11:00coffee break
11:00-11:12Periarticular histiocytic sarcoma (PAHS) – Epidemiology, clinical characteristics and prognosis in 70 dogs
dr. Julia Gedon
11:14-11:28Comparison of computed tomographic (CT) appearance of pulmonary involvement in localized and systemic histiocytic sarcoma in dogs
dr. Jan Wennemuth
11:30-12:15Clinical management of canine systemic histiocytic sarcoma: past, present and what is up on the horizon?
dr. Jane Dobson, Cambridge
12:15-12:45Round table discussionall speakers
12:45-13:00Welcome ESVONC to Frankfurt! – what to see and what to do!
dr. Martin Kessler
13:00-14:15Lunch

Resident abstracts
14:15-14:27Adjuvant dose-intense versus metronomic chemotherapy for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study
dr. Carmit Chalfon
14:29-14:41Is radiation therapy a useful treatment option for meningoencephalomyelitis of unknown origin in dogs?
dr. Maximilian Körner
14:43-14:55DNA double-strand breaks quantification in U87 cell-line exposed to 165Holmium, combined with ionizing radiation
dr. Pauline Denoeux
14:55-15:07Low dose metronomic cyclophosphamide as adjuvant treatment in feline mammary carcinomas – A preliminary evaluation
dr. Gonçalo Petrucci
15:10-15:40Coffee break

General abstracts
15:40-15:52Evaluation of a double deleted oncolytic Vaccinia virus encoding FCU1 protein in dogs diagnosed with malignant solid tumors
dr. Jérémy Béguin
15:55-16:07Canine anal sac adenocarcinoma with lymph node metastases treated with anal sacculectomy and lymphadenectomy: is there a need for a new staging system?
dr. Jean-Benoit Tanis
16:09-16:21Definitive radiation therapy for dogs with oral papillary squamous cell carcinoma.
dr. Francine van der Steen
16:30-17:30ESVONC Annual General Meeting (ESVONC members)

19:00-21:00Welcome reception on the river Main – see Frankfurt’s skyline by night
































Main Program - Friday 24 May 2019  

timetitlespeaker

Themed session: Inflammation and cancer

9:00-9:45Inflammation in cancer initiation and maintenance
prof. David Argyle, Edinburgh
9:45-10:30Inflammation in tumor progression and metastasis
prof. Florian Greten, Frankfurt
10:30-11:00Coffee break
11:00-11:30The role of Cyclooxygenase-2 in cancer stem cell survival and repopulation during anticancer therapy
dr. Lisa Pang, Edinburgh
11:30-12:00COX-2–independent anticarcinogenic effects of COX-Inhibitors
prof. Sabine Grösch, Frankfurt
12:00-12:30The use of COX-2 inhibitors in treating cancer: what’s the evidence?
prof. David Argyle, Edinburgh
12:30-13:00Panel discussion
13:00-14:15Poster session, and invited snack lunch in the industrial exhibition


General abstracts
14:15-14:27Expression of HIF-1 alpha and hypoxia-related markers correlate with prognosis in canine appendicular osteosarcoma
dr. Cecilia Gola
14:29-14:41Non-Injection site soft tissue sarcoma in cats: Outcome following adjuvant radiotherapy
dr. Alenka Lavra Zajc
14:43-14:55Using the dog’s definitive-intent radiotherapy protocol for sinonasal carcinomas in cats: a multicenter retrospective assessment
dr. Katerina Stiborova
14:57-15:09High-Resolution Transcriptome Analysis of Feline Mammary Carcinomas and derived cell lines
dr. Joé-Luis Granados Soler
15:20-15:50Coffee break
15:50-16:02Outcomes of canine subcutaneous mast cell tumours treated with adjunctive radiation therapy
dr. Begoña Pons Gil
16:02-16:14Radiotherapy Outcomes in Dogs with Solitary Plasma Cell Tumors: 29 Cases
dr. Blaise Burke
16:14-16:26Outcome of canine high-risk cutaneous mast cell tumours treated with adjuvant radiation therapy alone or combined with chemotherapy
dr. Onne-Marju Russak
16:26-16:38Malignant melanoma of the nasal planum in cats - A report of 6 cases
dr. Amalia Reck
16:38-16:50Discovery of chromosomal amplifications in canine oral melanoma as a new prognostic factor
dr. Anaïs Prouteau
16:50-17:02Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors
dr. Johannes Chad
19:30-??:??Gala Dinner in Gesellschaftshaus Palmengarten


Main program - Saturday 25 May 

timetitlespeaker
8:00-9:00Guided tour through Hofheim Veterinary Hospital (one of the largest private veterinary hospitals in Europe)


Themed session: pathologist – clinician interaction

9:15-10:00Key note lecture by chair: How do you get what you need? Problems and pitfalls in the pathologist – clinician interaction
prof. Marije Risselada, Purdue
10:00-10:45Determining resection margins as a pathologist – clean but close or too close to be clean?
dr. Annika Herrmann, Bristol
10:45-11:15Coffee break - visiting the poster exhibition
11:15-12:00On the cutting edge: a surgical oncologist’s perspective on resection margins
prof. Marije Risselada, Purdue
12:00-12:30Mitotic index, Ki67 – preanalytic complications, analytic variations and clinical implications
Jérôme Abadie, Nantes
12:30-13:00Panel discussion: Reporting resection margins, histologic grades  and proliferation markers – implications for postop decision making 
all speakers
13:00-14:15Lunch on your own

General abstracts
14:15-14:27Clinicopathologic characteristics, postoperative outcome and prognostic factors in 61 dogs with primary pulmonary carcinomas
dr. Tanja Plavec
14:27-14:39Lymphoma risk by clade and age of diagnosis as potential markers of genetic risk in dogs.
dr. Peter Bennett
14:40-15:00Announcement presentations for World Veterinary Cancer Conference 2020 Tokyo & ESVONC 2020 Syracusa

15:01-15:13
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers
dr. Laura Marconato
15:13-15:25Canine splenic masses: a systematic review of the literature for possible pre-surgical determinants of malignancy and creation of a new grading system
dr. Valerie J. Poirier
15:25-15:37USP7 inhibitor as a novel drug candidate for canine lymphoma/leukemia treatment
dr. Aleksandra Pawlak
15:37-15:49A novel aggressive T-cell lymphoma/leukemia in young dogs
dr. Paul Avery
15:49-16:01Canine multicentric lymphoma (CML): towards a European consensus for diagnostic imaging ?
dr. Catherine Ibisch
16:01-16:13Refining the double two-thirds rule: the importance of breed and clinical presentation to predict the diagnosis of canine splenic mass lesions in 288 dogs
dr. Owen Davies
16:15-16:30Farewell ceremony